DayTwo

DayTwo is a health technology company specializing in personalized nutrition and wellness solutions based on gut microbiome analysis. The company integrates gut microbiome sequencing, AI, and virtual care to provide a sustainable path to remission for metabolic diseases (i.e., diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease). 

The company offers gut microbiome profiling to predict blood sugar response to foods and dedicated virtual care. The main product of DayTwo is a glycemic-control solution, which is intended for persons with Type 2 diabetes. It is said to assist in balancing blood sugar levels, lowering HbA1C, and losing weight. 

Key customers and partnerships

In January 2024, the company partnered with Pragma Bio, a technology-driven drug discovery firm, to gain a thorough understanding of the connections between the human gut and Inflammatory Bowel Disease (IBD). This partnership prioritized using advanced technology and comprehensive patient data, including metagenomic data, to address unmet needs in the IBD field. The primary goal was to uncover biomarkers and develop therapeutics through foundational discoveries.

In November 2020, the company partnered with Florida Health Alliance to develop precision nutrition targeting metabolic disease.

Funding and Financials

In August 2021, DayTwo raised USD 37 million in funding to support the expansion of chronic disease solutions for employers, health plans, and health systems and to address the growing demand for its virtual care solution for metabolic diseases, including diabetes, prediabetes, and obesity.